Gabapentin

加巴喷丁

Report date: 2026/05/24 20:00:34
NME

Base Information

Drug NameGabapentin
Drug Alias Namegabapentine盖巴潘汀诺立汀gabapentinumgabapentina +[20] 
ClassificationSmall molecules
Mechanisms of ActionVoltage-gated calcium channel alpha2/delta subunit 2 blockersVoltage-gated N-type calcium channel alpha-1B subunit blockers
TargetsVoltage-gated N-type calcium channel alpha-1B subunitVoltage-gated calcium channel alpha2/delta subunit 2
Therapy Area/IndicationsDiabetic peripheral neuropathyCoronavirus Disease 2019 (COVID-19)Bipolar II Disorder +[71] 
Global Approved IndicationsAnxietyRestless Legs SyndromeNeuralgia, Postherpetic +[8] 
Approved Indications in ChinaEpilepsy
Original Approved Country/TerritoryUnited StatesJapan
Original Approved Date1993/12/30
Country/TerritoryCzechiaBelgiumCanada +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of California DavisWeill Medical College of Cornell UniversityGodecke Gmbh +[19] 
Inactive CompaniesUniversity Of Lille Nord De FranceViatrisFederal University Of Sao Paulo +[31] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Bipolar II DisorderBipolar I Disorder +[32] 
Inactive IndicationsDiabetic peripheral neuropathyPsychotic DisordersCognition Disorders +[39] 

Other Information

ATC CodeN02BF01
Related LinksWikipediaDrugBankKEGG